Cited by 688Neurogenetic and Muscular Disorders ResearchVirus-based gene therapy researchRNA Interference and Gene Delivery

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

Open access

Foust, Kevin D, Wang, Xueyong, McGovern, Vicki L, Braun, Lyndsey, Bevan, Adam K, Haidet, Amanda M, Le, Thanh T, Morales, Pablo R, Rich, Mark M, Burghes, Arthur H M, Kaspar, Brian K·2010·Nature Biotechnology

DOI 10.1038/nbt.1610PMC PMC2889698

Open this paper in CoChat — free account

Abstract

Spinal muscular atrophy (SMA), the most common autosomal recessive neurodegenerative disease affecting children, results in impaired motor neuron function. Despite knowledge of the pathogenic role of decreased survival motor neuron (SMN) protein levels, efforts to increase SMN have not resulted in a treatment for patients. We recently demonstrated that self-complementary adeno-associated virus 9 (scAAV9) can infect approximately 60% of motor neurons when injected intravenously into neonatal mice. Here we use scAAV9-mediated postnatal day 1 vascular gene delivery to replace SMN in SMA pups and rescue motor function, neuromuscular physiology and life span. Treatment on postnatal day 5 results in partial correction, whereas postnatal day 10 treatment has little effect, suggesting a developmental period in which scAAV9 therapy has maximal benefit. Notably, we also show extensive scAAV9-mediated motor neuron transduction after injection into a newborn cynomolgus macaque. This demonstration that scAAV9 traverses the blood-brain barrier in a nonhuman primate emphasizes the clinical potential of scAAV9 gene therapy for SMA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nbt.1610This paper is marked retracted.

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Bénichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,995
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citation
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-/- mice and results in a mouse with spinal muscular atrophy
Monani, U. R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.3.333 · Cited by 745
Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?
Burghes, A. H. M., & Beattie, C. E. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2670 · Cited by 723
Self-citation
SMNΔ7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN
Le, T. T., Pham, L. T., Butchbach, M. E. R., Zhang, H. L., Monani, U. R., Coovert, D. D., Gavrilina, T. O., Xing, L., Bassell, G. J., & Burghes, A. H. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi078 · Cited by 600
Self-citation
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo
McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 1×
“Advances in vector design, such as AAV capsid modification, mutagenesis or gene shuffling, may expand the opportunity to target neurons in the adul”
BackgroundSelf-citation
Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue
Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522
Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511

Flagged first, then by citations

Show all 30 references

Sorted by citations

Items 601–687 of 687

Translational Medicine: Evolution, Fulfillment, and Belief in Gene Therapy
Mendell, J. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.29103.jrm · Cited by 2
Spinal Muscular Atrophy: Huge Steps.
Howell, K., Gibbs, R. M., & Rubin, L. L. (2019) · PubMed Central · Cited by 2
Inherited Neuromuscular Disease
Kichula, E. A., Ferguson, T. A., & Lynch, D. R. (2017) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0005513.pub2 · Cited by 2
Trans -Splicing, More Than Meets the Eye: Multifaceted Therapeutics for Spinal Muscular Atrophy
Butchbach, M. E. R. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.903 · Cited by 2
AAV-mediated ARSA replacement for the treatment of Metachromatic LeukodystrophyPreprint
Ramachandran, S., Ardinger, J., Bu, J., Ramos, M., Guo, L., Ghosh, D., Hossain, M., Chou, S.-C., Chen, Y., Wischhof, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.12.642609 · Cited by 2
Current Treatment Process and Challenges for Spinal Muscular Atrophy (SMA)
Mishra, N. K., Mishra, A., Sahoo, P. K., & Priyadarshini, R. (2024) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2024.00580 · Cited by 1
Recent Advance in Disease Modifying Therapies for Spinal Muscular Atrophy
Tsai, L., Ting, C.-H., Liu, Y., Hsiao, C.-T., Weng, W., & Society for Neurological Rare Disorders-Taiwan (2024) · Acta Neurologica Taiwanica · doi:10.4103/ant.33-3_review · Cited by 1
Discovery, SAR and Biological Evaluation of Aryl-thiazol-piperidines as SMN Modulators
Xiao, J., Marugán, J., Zheng, W., Titus, S., Southall, N. T., Cherry, J. J., Evans, M. C., Androphy, E. J., & Austin, C. P. (2011) · Cited by 1
CNS Gene Therapy Utilizing Intravenously Administered Viral Vectors
Bevan, A. K., & Kaspar, B. K. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_17 · Cited by 1
Self-citation
AAV6-Mediated Gene Silencing fALS Short
Mandel, R. J., Lowenstein, P. R., & Byrne, B. J. (2011) · Molecular Therapy · doi:10.1038/mt.2010.306 · Cited by 1
Prolactin for spinal muscular atrophy
Lou, K.-J. (2011) · Science-Business eXchange · doi:10.1038/scibx.2011.896 · Cited by 1
Als in California: A Report From the First Annual California Als Research Summit
Sea, K. W., Gowing, G., Joyce, N. C., Barber, J., Fisher, F., Miller, R. G., Rasmussen, D., Smith, R. A., Valentine, J. S., Wolff, J. M., et al. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.37 · Cited by 1
Current and investigational treatments for spinal muscular atrophy
Tam, J. K. V., Karyka, E., & Azzouz, M. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.901910 · Cited by 1
An Introduction to the Natural History, Genetic Mapping, and Clinical Spectrum of Spinal Muscular Atrophy
Mcdonough, A. M., Urquia, L. N., & Boulis, N. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802257-3.00005-5 · Cited by 1
Gene Therapy for Spinal Muscular Atrophy
Miller, M. R., Osman, E. Y., & Lorson, C. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802257-3.00010-9 · Cited by 1
Facilitating orphan drug development: Proceedings of the TREAT-NMD International Conference, December 2015, Washington, DC, USA
Hoffman, E. P., Bönnemann, C. G., Boutin, M., Brais, B., Buccella, F., Burghes, A. H. M., Coffey, C. S., Dasgupta, N., Dawkins, H. J. S., Luca, A. D., et al. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.02.013 · Cited by 1
Self-citation
Spinal Muscular Atrophy: Entering the Treatment Age
Kichula, E. A., Yum, S. W., & Brandsema, J. F. (2018) · Current Pediatrics Reports · doi:10.1007/s40124-018-0150-2 · Cited by 1
Induced pluripotent stem cells for modeling of spinal muscular atrophy
Welby, E., & Ebert, A. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85764-2.00010-7 · Cited by 1
Transduction profiles in minipig following MRI guided delivery of AAV-5 into thalamic and corona radiata areas
Pietersz, K. L., Pouw, S. M., Klı́ma, J., Ellederová, Z., Bohuslavová, B., Chrastina, J., Liscak, R., Urgošík, D., Stárek, Z., Crha, M., et al. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109382 · Cited by 1
SLC6A1 and Neuropsychiatric Diseases: The Role of Mutations and Prospects for Treatment with Genome Editing Systems
Букина, Е. С., Kondratyev, N. V., Kozin, S. V., Голимбет, В. Е., Artyuhov, A., & Dashinimaev, E. B. (2021) · Neurochemical Journal · doi:10.1134/s1819712421040048 · Cited by 1
Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of SMN2 in SMA Type I Fibroblasts
Toosaranont, J., Ruschadaariyachat, S., Mujchariyakul, W., Arora, J. K., Charoensawan, V., Suktitipat, B., Palmer, T. N., Fletcher, S., Wilton, S. D., & Mitrpant, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073937 · Cited by 1
Advanced therapies in rare diseases: The example of spinal muscular atrophy
Tizzano, E. F. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.03.025 · Cited by 1
Lessons from Real Life Experience: Importance of In-House Sequencing and Smart Ratio-Based Real-Time PCR Outperform Multiplex Ligation-Dependent Probe Amplification in Prenatal Diagnosis for Spinal Muscular Atrophy: Bench to Bedside Diagnosis
Tuncel, G., Şanlıdağ, B., Dırık, E., Baris, T., Ergören, M. Ç., & Temel, Ş. G. (2023) · Global Medical Genetics · doi:10.1055/s-0043-1774307 · Cited by 1
Spinal Musküler Atrofi: Tanı, Tarama ve Tedavide Güncel Gelişmeler
YÜCEL, Z., & YÜKSEL, E. B. (2023) · Journal of General Health Sciences (JGEHES) Necmettin Erbakan University · doi:10.51123/jgehes.2023.92 · Cited by 1
SMN2 Splicing Modification by Small Molecules – A Blueprint to Tackle the Underlying Genetic Cause of Many Underserved Diseases
Ratni, H., Ebeling, M., Scalco, R., Mueller, L. A., & Stephan, A. H. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00830 · Cited by 1
Approaches to pathogenetic therapy of spinal muscular atrophy in children and newborns
Artemyeva, S. B., Shidlovskaya, О. А., Papina, Y. О., Monakhova, А. V., Shulyakova, I. V., Белоусова, Е. Д., Germanenko, O. Y., & Владимирович, В. Д. (2024) · Neuromuscular Diseases · doi:10.17650/2222-8721-2024-14-1-86-92 · Cited by 1
Novel treatments for neurodegenerative disorders predominantly presenting in children and young adults
Ward, D. I., Saifeddine, M., & Gogoi, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95735-9.00046-2 · Cited by 1
Bibliometrics and Visualization Analysis of Neuromuscular Junction Model
Du, X., Liu, W., Geng, J., Qiao, H., & Zhou, Y. (2025) · Neurology India · doi:10.4103/ni.ni_385_22 · Cited by 2
Systemic Gene Therapy for Targeting the CNS
Gombash, S. E., & Foust, K. D. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3271-9_16 · Cited by 1
Self-citation
Spinal muscular atrophy
Waldrop, M. A., Kolb, S. J., Kissel, J. T., & Elsheikh, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00014-5 · Cited by 1
Gene Therapy for Neurodevelopmental Disorders
McCarty, D. M., & Fu, H. (2014) · Wiley eBooks · doi:10.1002/9780470015902.a0025276 · Cited by 1
Getting a fix on SMA
Dolgin, E. (2012) · Nature Medicine · doi:10.1038/nm1112-1605 · Cited by 1
Central and peripheral delivery of AAV9-SMN target different pathomechanisms in a mouse model of spinal muscular atrophyPreprint
Reilly, A., Deguise, M., Beauvais, A., Yaworski, R., Thebault, S., Tessier, D. R., Tabard‐Cossa, V., Hensel, N., Schneider, B. L., & Kothary, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.08.467795 · Cited by 1
Using the natural resistance of motor neuron subpopulations to identify therapeutic targets in amyotrophic lateral sclerosis
Spiller, K. J. (2014) · doi:10.7916/d8fn145w
Modeling Spinal Muscular Atrophy in Mouse: A Disease of Splicing, Stability, and Timing
Thomas, W., & Dawn, S. (2011) · InTech eBooks · doi:10.5772/29013
Development of Therapies for Spinal Muscular Atrophy Using Gene Therapy and Nanotechnology
Little, D. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
GLT-1 over-expression attenuates visceral nociception by pharmacological and gene therapy approaches
Roman, K. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
Gene Therapy in SMA Mice Has Experts Talking About Potential for Human Trials and Genetic Screening
Robinson, R. (2010) · Neurology Today · doi:10.1097/01.nt.0000383482.61535.6e
Role of p38 and STAT5 Kinase Pathways in the Regulation of Survival of Motor Neuron Gene Expression for Development of Novel Spinal Muscular Atrophy Therapeutics
Farooq, F. (2012) · uO Research (University of Ottawa) · doi:10.20381/ruor-3135
Gene Therapy for Motor Neuron Disease
Boulis, N. M. (2011)
GENETIC ANIMAL MODELS OF TOURETTE SYNDROME: THE LONG AND WINDING ROAD
Cauchi, R. J., & Tárnok, Z. (2012)
Application of Viral Vectors to Motor Neuron Disorders
Dirren, E., & Schneider, B. L. (2013) · Neuromethods · doi:10.1007/978-1-62703-610-8_12
Gene Therapy in Spinal Muscular Atrophy (SMA) Models Using Intracerebroventricular Injection into Neonatal Mice
Shababi, M., Osman, E. Y., & Lorson, C. L. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_12
Gene Transfer in Spinal Muscular Atrophy
Foust, K. D., & Kaspar, B. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00019-7
Self-citation
Defining the therapeutic window in spinal muscular atrophy :||time points study
Robbins, K. L. (2013) · doi:10.32469/10355/44711
Virus-mediated Delivery of the Fmr1 Gene as a Tool for the Treatment of Fragile X Syndrome
Moghaddam, S. G. (2016) · TSpace (University of Toronto)
Inherited Neuromuscular Disorders: Presentation, Diagnosis, and Advances in Treatment
Kichula, E. A. (2017) · Current Pediatrics Reports · doi:10.1007/s40124-017-0118-7
Development and Translation of Therapies for Spinal Muscular Atrophy
Shorrock, H. K., & Gillingwater, T. H. (2016) · EMJ Neurology · doi:10.33590/emjneurol/10312757
Role of Gigaxonin in the Regulation of Intermediate Filaments: a Study Using Giant Axonal Neuropathy Patient-Derived Induced Pluripotent Stem Cell-Motor Neurons
Johnson-Kerner, B. (2013) · doi:10.7916/d8z324c3
Defining the anti-apoptotic function of the survival of motor neuron (SMN) protein and assessment of a novel therapy for the treatment of spinal muscular atrophy (SMA)
Anderton, R. S. (2014) · UWA Profiles and Research Repository (University of Western Australia)
Therapeutic strategies for spinal muscular atrophy: looking beyond the SMN gene
Bowerman, M., Becker, C. G., Yáñez‐Muñoz, R. J., Ning, K., Wood, M. J. A., Gillingwater, T. H., & Talbot, K. (2017) · Disease Models & Mechanisms
Gene Therapy Approaches for Neurological Lysosomal Storage Diseases
McCurdy, V. J. (2014)
Cellular Therapy for Spinal Muscular Atrophy
Faravelli, I., & Corti, S. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802257-3.00011-0
Targeting the ubiquitin proteasome system to develop novel therapeutic approaches for spinal muscular atrophy
Powis, R. A. (2016) · Edinburgh Research Archive (University of Edinburgh)
Gene-Based Neuromodulation
Tomasiewicz, H. C., Kocharian, G., & Kaplitt, M. G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-805353-9.00030-9
The Path to Therapeutics Development for Spinal Muscular Atrophy ∗ ∗This article by K. H. Fischbeck is in public domain.
Fischbeck, K. H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.06003-1
Awards for research on Rett syndrome: towards a therapeutic breakthrough
Egebjerg, J., & Morris, R. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30212-x
Translating molecular therapies for spinal muscular atrophy
Kaspar, B. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00017-3
Self-citation
Identification of a Novel Class of Small Molecules for Spinal Muscular Atrophy Through High-throughput Phenotypic Screening
Swalley, S. E., & Cheung, A. K. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160721-00140
Translation of gene therapies
Layer, R. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00035-0
Translational research in drug discovery: Tiny steps before the giant leap
Upadrasta, S., & Yadav, V. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821972-0.00010-1
Controlling Transgene Expression in the Central Nervous System For MRI-Guided Focused Ultrasound Delivery of Adeno-Associated Virus
Weber‐Adrian, D. (2017) · TSpace (University of Toronto)
Gentherapie bei spinaler Muskelatrophie -ein Update
Brakemeier, S., Kleinschnitz, C., & Hagenacker, T. (2021) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-021-1916-6
Nusinersen, an exon 7 inclusion drug for spinal muscular atrophy: A minireview
Behera, B. (2021) · World Journal of Meta-Analysis · doi:10.13105/wjma.v9.i3.277
An evaluation of onasemnogene abeparvovec for spinal muscular atrophy (SMN1)
Waldrop, M. A., Connolly, A. M., & Mendell, J. R. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.2003778
Current World Literature
(2010) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32834179f9
Faculty Opinions recommendation of Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Fletcher, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727480507.793560197
Gene Therapy
Malgieri, A., Spitalieri, P., Novelli, G., & Sangiuolo, F. C. (2010) · Springer eBooks · doi:10.1007/978-88-470-1658-3_8
Diagnostische Verfahren
(2019) · Elsevier eBooks · doi:10.1016/b978-3-437-21882-8.00026-8
Cribado neonatal en atrofia muscular espinal: un desafío para cambiar la historia natural
Rausei, J. (2021) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/revhospitalbaires.v41i2.89
Eli Lilly to Acquire Akouos for up to $610M
Philippidis, A. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.29227.bfs
Treatment for Spinal Muscular Atrophy Using Onasemnogene Abeparvovec
Bekircan‐Kurt, C. E., Waldrop, M. A., Connolly, A. M., & Mendell, J. R. (2022) · touchREVIEWS in Neurology · doi:10.17925/usn.2022.18.2.133
Gene Therapy Drug Development for First-In-Human Study of Pediatric Diseases: Facilitating Change to Current Paradigms
Rayapudi, P., Robinson, P. M., Mangas, E., & Mulberg, A. E. (2023) · Medical Research Archives · doi:10.18103/mra.v11i7.2.4159
Literaturverzeichnis
(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-21884-2.00033-7
Additional file 1 of Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years
Vill, K., Schwartz, O., Blaschek, A., Gläser, D., Nennstiel, U., Wirth, B., Burggraf, S., Röschinger, W., Becker, M., Czibere, L., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14355526
Additional file 2 of Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years
Vill, K., Schwartz, O., Blaschek, A., Gläser, D., Nennstiel, U., Wirth, B., Burggraf, S., Röschinger, W., Becker, M., Czibere, L., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14355529
Gene therapy
Владимирович, М. А., Анатольевна, С. С., Nikitin, S., Adyan, T., Akhkiamova, M., Borovikov, A. O., Buharova, T., Efimova, I. E., Zharkov, P., Kadyshev, V. V., et al. (2026) · doi:10.29039/978-5-94472-329-1-02-2026
Survival motor neuron protein-independent amelioration of spinal muscular atrophy by pharmacological inhibition of c-Jun-NH2 terminal kinase
Kannan, A., Bhatia, K., Jiang, X., Lesnik, O., Asad, S. B., Fiocca, K., Ahmad, S., Feng, Y., Branzei, D., & Gangwani, L. (2026) · Brain Communications · doi:10.1093/braincomms/fcag111
Étude du rôle du complexe SMN dans l’assemblage de RNP non codantes ubiquitaires : la SRP, les RNP C/D et H/ACA dont la télomérase, et étude du taux des facteurs d’assemblage de la télomérase dans les cellules cancéreuses
Dodré, M. (2014) · theses.fr (ABES) · doi:10.70675/b97d6973z95aaz4364z8030z3b86fc1d910d
Thérapie génique pour l’amyotrophie spinale à l’aide de vecteur AAV
Besse, A. (2019) · theses.fr (ABES) · doi:10.70675/4c95aab3zb74dz4adbzae72z8c836167d9ba
Study of the involvement of the IRE1α-XBP1 branch of unfolded urotein response in spinal muscular atrophy
D'amico, D. (2020) · theses.fr (ABES) · doi:10.70675/6e54c5b3zdabfz4677z9604zfcce72b7ed92
Проследяване на ефекта от лечението със Spinraza (Nusinersen) при български пациенти със спинална мускулна атрофия (СМА) над 18 г.
Chamova, T., Angelov, T., Тодоров, Т., Чобанов, К., Димитрова, Т., Танчева, М., Ковачева, Р., Тодорова, А., & Tournev, I. (2023) · Българска неврология · doi:10.67667/neu.v24i2.139
Spinal muscular atrophy: Biology, pathogenesis, and therapeutic advances
René, C. A., & Parks, R. J. (2026) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864261480901
Spinal Müsküler Atrofi
Cankar, B., & TAŞ, E. (2026) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub1443.c5819
The role of vascular pathology in SMA: implications for pathogenesis and treatment
Parson, S. H., & Allardyce, H. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1933459
BindingDB Entry 50033854: Discovery, synthesis, and biological evaluation of novel SMN protein modulators.
BindingDB (2012) · UC San Diego · doi:10.7270/q22f7nvf
rAAV-Mediated Gene Transfer For Study of Pathological Mechanisms and Therapeutic Intervention in Canavan's Disease: A Dissertation
Ahmed, S. S. (2014) · eScholarship@UMassChan · doi:10.13028/m25s3r

Authors: Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., & Kaspar, B. K.
Affiliations: Nationwide Children's Hospital (US)
Wright State University (US)
The Ohio State University (US)
Corresponding author: Kaspar, Brian K
ORCID: Foust, Kevin D
Wang, Xueyong
McGovern, Vicki L
Le, Thanh T
Morales, Pablo R
Rich, Mark M
Burghes, Arthur H M
Kaspar, Brian K
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2010-02-28
Volume: 28
Issue: 3
Pages: 271-274
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.1610
PMC: PMC2889698
OpenAlex: W2045117117
Cited by: 688
References: 30
Citations by year: 2026: 5 · 2025: 10 · 2024: 17 · 2023: 19 · 2022: 42 · 2021: 49 · 2020: 61 · 2019: 51 · 2018: 32 · 2017: 56 · 2016: 48 · 2015: 51 · 2014: 57 · 2013: 54 · 2012: 48
FWCI: 27.28
Type: journal article
Language: en
Status: Retracted
Update notices: retraction (2022-10-06)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
CORE Scholar (Wright State University) (submittedVersion)
Journal of Bioresource Management (submittedVersion)
Funders: National Institute of Neurological Disorders and Stroke (R21NS064328, RC2NS069476, P30NS045758, P01NS057228, R01NS038650, F31NS058224)
Topics: Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: spinal muscular atrophy, gene therapy, motor neurons, blood-brain barrier, cynomolgus macaques, mouse model, retraction
MeSH terms: Dependovirus, Animals, Animals, Newborn, Disease Models, Animal, Macaca fascicularis, Male, Mice, Transgenic, Microscopy, Fluorescence, Motor Neurons, Muscular Atrophy, Spinal, Phenotype, Gene Transfer Techniques, Green Fluorescent Proteins, Mice, Kaplan-Meier Estimate, Survival of Motor Neuron 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks